Predicting In-Hospital Outcomes of Patients with Acute Kidney Injury

Wu, Changwei; Zhang, Yun; Nie, Sheng; Hong, Daqing; Liu, Bi‐Cheng; Liu, Huafeng; Yang, Qiongqiong; Li, Hua; Xu, Gang; Weng, Jianping; Kong, Yaozhong; Wan, Qijun; Zha, Yan; Chen, Chunbo; Xu, Hong; Hu, Ying; Shi, Yongjun; Zhou, Yilun; Su, Guobin; Tang, Ying; Gong, Mengchun; Wang, Li; Hou, Fanfan; Liu, Yongguo; Li, Guisen

doi:10.2139/ssrn.4289478

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Urine output criteria were not applied because urine volume was not available in this study. The dynamic algorithm has been described elsewhere 23,29,30 and in Supplemental Method 2. We staged AKI by the peak increase in serum creatinine from the baseline, with levels of <100%, 100%–199%, and ≥200%, peak serum creatinine >4 mg/dl or initiation of KRT defined as stage 1, 2, or 3, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…The detailed information about CRDS database was described in our previous publications. 23–26 The study protocol was approved by the Medical Ethics Committee of Nanfang Hospital, Southern Medical University (approval number: NFEC-2019-213), which waived the requirement for informed patient consent because of the retrospective nature of the study and anonymization of the dataset. This study was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Associations between Different Antivirals and Hospital-Acquired Acute Kidney Injury in Adults with Herpes Zoster

Xu,

Gao,

Zhang

et al. 2024

CJASN

View full text Add to dashboard Cite

Background: To examine the association of use of different antivirals with hospital acquired acute kidney injury (AKI) among Chinese adults with herpes zoster. Methods: The study selected 3273 adult patients who received antiviral therapy for herpes zoster during hospitalization from the China Renal Data System (CRDS). We identified and staged AKI using patient-level serum creatinine data according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria. We compared the relative risks of hospital acquired AKI among patients treated with different antivirals using Cox proportional hazards models. Results: Among 3273 patients, 1480 (45%), 681 (21%), 489 (15%) and 623 (19%) were treated with acyclovir/valacyclovir, ganciclovir, penciclovir/famciclovir, and foscarnet, respectively. During the follow-up period, a total of 111 cases of hospital acquired AKI occurred, predominantly classified as AKI stage 1. The cumulative incidences of hospital acquired AKI were 5%, 3%, 3% and 1%, in the patients receiving acyclovir/valacyclovir, ganciclovir, penciclovir/famciclovir, and foscarnet, respectively. Compared with acyclovir/valacyclovir, penciclovir/famciclovir/ganciclovir and foscarnet were associated with a lower risk of hospital acquired AKI, with an adjusted hazard ratio [aHR] of 0.59 (95% CI, 0.37-0.94) and 0.27 (95% CI, 0.11-0.63), respectively. Compared with intravenous acyclovir, intravenous penciclovir/ganciclovir and foscarnet were associated with a lower risk of hospital acquired AKI with an aHR of 0.53 (95% CI, 0.29-0.98) and 0.31 (95% CI, 0.12-0.76), respectively. The associations were consistent across various subgroups and sensitivity analyses. Conclusions: Among antiviral therapies for herpes zoster, we found different risks of hospital acquired AKI among the patients receiving different antivirals, in particular, those administered intravenously. Among intravenous antivirals, acyclovir was associated with highest risk of hospital acquired AKI, followed by penciclovir/ganciclovir and foscarnet. Confirmation studies with large samples from other populations are warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%